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http://dx.doi.org/10.1016/j.stemcr.2017.01.027SUMMARYFamilial hypercholesterolemia (FH) causes elevation of low-density lipoprotein cholesterol (LDL-C) in blood and carries an increased risk
of early-onset cardiovascular disease. A caveat for exploration of new therapies for FH is the lack of adequate experimental models. We
have created a comprehensive FH stem cell model with differentiated hepatocytes (iHeps) from human induced pluripotent stem cells
(iPSCs), including genetically engineered iPSCs, for testing therapies for FH.We used FH iHeps to assess the effect of simvastatin and pro-
protein convertase subtilisin/kexin type 9 (PCSK9) antibodies on LDL-C uptake and cholesterol lowering in vitro. In addition, we en-
grafted FH iHeps into the liver of Ldlr//Rag2//Il2rg/ mice, and assessed the effect of these same medications on LDL-C clearance
and endothelium-dependent vasodilation in vivo. Our iHep models recapitulate clinical observations of higher potency of PCSK9 anti-
bodies compared with statins for reversing the consequences of FH, demonstrating the utility for preclinical testing of new therapies for
FH patients.INTRODUCTION
Mutations in LDLR (encoding LDL receptor, LDLR), often
heterozygous, underlie most cases of familial hypercho-
lesterolemia (FH), which predisposes to premature car-
diovascular disease due to marked elevation of plasma
levels of lipids, in particular low-density lipoprotein
cholesterol (LDL-C) (Brown and Goldstein, 1986). Be-
sides diet control and physical activity, FH patients are
treated with statins, a class of drugs that inhibit 3-hy-
droxy-3-methylglutaryl-coenzyme A (HMG-CoA) reduc-
tase and hence reduce cholesterol synthesis in the
liver (Endo, 1992). Statins also increase LDLR protein
levels in hepatocytes and LDL-C clearance from plasma.
Because of these properties, statins are used to treat
FH patients and also patients with non-familial hyper-
cholesterolemia. However, statins fail to reduce plasma
LDL-C adequately in the majority of these patients forStem Ce
This is an open access article under the Cprevention of cardiovascular events (Cannon et al.,
2015; Reiner, 2015), and a proportion of patients suffers
from significant adverse effects (Dormuth et al., 2014;
Stroes et al., 2015).
Importantly, FH can be caused by mutations in other
genes besides LDLR, including gain-of-function mutations
in proprotein convertase subtilisin/kexin type 9 (PCSK9)
(Sniderman et al., 2014). This observation led to the sub-
sequent identification of PCSK9 as an extracellular protein
responsible for the internalization and degradation of
surface LDLR in hepatocytes (Maxwell et al., 2005). Inter-
estingly, PCSK9 is induced by statins, and activates a nega-
tive feedback loop that controls LDLR expression and
consequently restrains the efficacy of statins (Dubuc
et al., 2004). The latter may account for the limited effi-
cacy or even loss of efficacy of statins in some patients,
and has suggested that PCSK9 modulation could be of
therapeutic relevance. In this regard, clinical trials withll Reports j Vol. 8 j 605–618 j March 14, 2017 j ª 2017 The Authors. 605
C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
anti-PCSK9 therapy (in the form of monoclonal anti-
bodies) have shown potent lowering effects on LDL-C
and good tolerance, creating a tremendous interest in
this approach as an alternative medication for hypercho-
lesterolemia (Robinson et al., 2015; Roth et al., 2012).
Besides the potential paradigm shift in FH treatment,
these findings imply that interfering with additional
components of the LDLR degradation pathway (besides
PCSK9) may provide alternative therapeutic avenues for
hypercholesterolemia.
Despite the exciting developments with PCSK9 anti-
bodies, a relevant caveat for further exploration of
new therapies (new drugs or new formulations) for
FH (and also other genetic liver diseases) is the lack of
easily accessible and bona fide in vitro and in vivo
models for preclinical testing. In vitro models for
FH are mostly based on patient-derived hepatocytes
from liver biopsy (Cayo et al., 2012), which have
limited accessibility and cannot be expanded in culture.
In vivo models including the hyperlipidemic rabbit, the
rhesus macaque, and the Ldlr knockout mouse, have
the limitation of not fully recapitulating human hepato-
cyte function (Bissig-Choisat et al., 2015). Patient-spe-
cific induced pluripotent stem cells (iPSCs) can provide
an unlimited source of differentiated cell types including
hepatocytes (iHeps) that can be used for in vitro and
in vivo studies (Grskovic et al., 2011; Takahashi et al.,
2007). This approach combined with the transplantation
into immunodeficient mice may help overcome existing
problems in modeling FH in vitro and in vivo (Carpent-
ier et al., 2014; Chen et al., 2012; Liu et al., 2011). Several
groups have generated FH iPSCs that harbor mutations
in LDLR (Cayo et al., 2012; Ramakrishnan et al., 2015;
Rashid et al., 2010) or PCSK9 (Si-Tayeb et al., 2016) and
have tested the ability of the derived iHeps to mimic
the disease phenotype and respond to statins in vitro.
However, there are no reports so far testing the effect
of anti-PCSK9 therapies on FH iPSC-derived iHeps
in vitro, or in vivo disease modeling and drug testing
with FH iHeps transplanted into appropriate animal
models.
Here, we report that FH iHeps derived from patient-
specific and genetically engineered FH iPSCs can be
used to test the efficacy of two well-known medications
for lowering LDL-C, statins and PCSK9 antibodies, not
only in vitro but also in vivo, by engrafting FH iHeps
into the liver of immunodeficient mice knockout for
Ldlr. With these assays, we have confirmed clinical
observations of higher potency of PCSK9 antibodies
compared with statins for treating FH (Robinson et al.,
2015), indicating the potential of our model for further
drug discovery and preclinical testing of experimental
therapies.606 Stem Cell Reports j Vol. 8 j 605–618 j March 14, 2017RESULTS
Generation of a Panel of Patient-Specific and
Genetically Engineered FH iPSCs for In Vitro and
In Vivo Studies
We selected a family with clinical FH due to hetero-
zygous duplication of ‘‘TGCTGGC’’ (c.2108_2114dup,
p.Ala705fsX14) in exon 14 of LDLR (Khoo et al., 2000) (Fig-
ures 1A and 1B), which results in a premature stop codon.
Using urinary cells as a donor cell source (Benda et al.,
2013; Zhou et al., 2011) and episomal vectors as the reprog-
ramming method (Yu et al., 2009), we generated integra-
tion-free iPSCs from the two affected sisters (FH-1 and
FH-2) and the healthy sister (wild-type, WT) (Figures 1A
and S1A); individual clones for each person were selected
for further study. The resulting cell lines were fully plurip-
otent as shown by immunofluorescence (SSEA-4 and
NANOG), RT-qPCR (OCT4, SOX2, NANOG, and TERT),
DNA demethylation of the NANOG proximal promoter,
and the formation of teratomas in immunocompromised
mice (Figures S1B–S1E). Moreover, their karyotypes were
normal (Figure S1C) and after serial passaging there was
no remnant of the episomal vectors employed for reprog-
ramming, as tested by PCR (Figure S1F). We also confirmed
the LDLR mutation and the reduced expression of LDLR
protein in the two FH iPSC clones by sequencing and west-
ern blotting, respectively (Figures 1B and 1C).
Next, because variations in the genetic background
among iPSCs can be a confounding factor for in vitro dis-
easemodeling (Soldner et al., 2011),we used zinc-finger nu-
cleases (ZFNs) (Moehle et al., 2007) targetingexon4ofLDLR
(Figure S2A) to create a panel of isogenic LDLR knockout
iPSCs in a previously generated and well-characterized uri-
nary iPSC clone from an unaffected individual (Zhou
et al., 2011). This produced two biallelic knockout clones
and 27 monoallelic knockout clones out of 214 clones
screened by sequencing (Figure S2B). Of the resulting cell
lines, we selected one monoallelic knockout (+/) clone,
one biallelic knockout (/) clone, and the unmodified
control (+/+) as a panel for further study (Figure 1D). These
isogenic iPSCs retained pluripotency, displayed normal
karyotypes, and expressed LDLR levels according to their
genotypes (Figures 1C, S2C, and S2D). Therefore, we have
generated two complementary panels of iPSCs for studying
FH mechanisms and performing drug screening.PCSK9 Antibodies Show Stronger LDL-Lowering
Ability than Statins in FH iHeps
We differentiated our panel of patient-specific and isogenic
FH iPSCs into functional iHeps with a previously reported
three-step protocol (Kajiwara et al., 2012). After 17 days
of differentiation, iHeps with equivalent morphology to
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Figure 1. Generation of a Panel of FH iPSCs
(A) Family tree of WT and FH patients. Asterisk indicates patient-specific iPSCs generated in this study.
(B) Schematic depicting the genomic region of LDLR mutations in FH iPSCs. The boxed area indicates the position of heterozygous
duplicate of ‘‘TGCTGGC’’ in FH-1 iPSCs.
(C) Western blotting shows LDLR levels in HepG2 cells (control) and iPSCs. ACTIN was used as loading control.
(D) Genotype of a panel of FH isogenic knockout iPSC clones. Red labels the interval of both ZFN-recognized fragments; black in lowercase
among the red indicates insertion that resulted in frameshift.
(E) Phase contrast and immunofluorescence for ASGPR and A1AT of iHeps at day 17 of differentiation. Scale bars represent 50 mm.
(F) Bar graph shows the percentage of ASGPR+ iHeps obtained with our differentiation protocol as measured by flow cytometry.
A representative experiment with samples measured in triplicate is shown; error bars indicate SD.
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Figure 2. PCSK9 Antibodies Have a Stronger Effect than Statins on LDL Uptake by FH iHeps In Vitro
(A) Micrographs show co-localization of fluorescently labeled LDL (green) and HNF4A (red). Scale bars represent 50 mm.
(B) Left panel: bar graph shows percentage of DiI-LDL capture by flow cytometry in ASGPR+ iHeps with or without simvastatin. Statistical
tests were performed with three independent experiments; p values are indicated on the graph and were obtained using two-way ANOVA
adjusted with Tukey’s multiple comparison. Error bars indicate SEM. Middle and right panels: bar graphs show concentration of TC and APOB
secretion in iHeps culture as determined by ELISA; values were normalized by the concentration of secreted hALB. Statistical tests were
(legend continued on next page)
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human hepatocytes appeared (Figure 1E). These iHeps
displayedmarkers of primary hepatocytes including asialo-
glycoprotein receptor (ASGPR) and a1-antitrypsin (A1AT)
(Figure 1E), stored glycogen and lipids, secreted albumin
and urea, and had the ability to metabolize rifampicin via
the cytochrome P450 pathway (Figures S3A–S3E). Impor-
tantly, the efficiency of iHep differentiation between pa-
tient-specific and isogenic FH iPSCs was comparable, as
measured by analyzing the population of ASGPR+ cells by
flow cytometry (Figure 1F).
To reveal the main phenotypic feature of FH (inability to
uptake plasma LDL-C by hepatocytes) in vitro, we incu-
bated iHeps from the various iPSC lines with 5 mg/mL fluo-
rescently labeled LDL for 3.5 hr, followed by co-staining
with hepatocyte nuclear factor 4a (HNF4A) to confirm
the identity of the iHeps. As expected, WT and +/+ iHeps
showed high—and rather comparable—LDL uptake while
this was significantly impaired in FH-1, FH-2, and +/
iHeps, and completely abolished in / iHeps (Figure 2A).
Similar results were obtained when LDL capture was
measured using flow cytometry and normalized by the
number of ASGPR+ cells (Figure 2B, left panel). With the
same assay, we also observed that 10 mM simvastatin
elevated LDL uptake in FH-1 iHeps and +/ iHeps (Fig-
ure 2B, left panel), andmoremodestly inWTand +/+ iHeps.
However, there was only marginal basal LDL uptake,
without elevation with simvastatin, in / iHeps (Fig-
ure 2B, left panel). In addition, we measured total choles-
terol (TC) and apolipoprotein B (APOB) secretion (an
indirect measure of LDL secretion) (Cayo et al., 2012) in
our panel of iHeps. TC and APOB were increased in FH-1
iHeps compared with WT, and in +/ and / iHeps
compared with +/+ iHeps (Figure 2B, middle and right
panels). On the other hand, 10 mM simvastatin reduced
TC and APOB levels in iHeps from all tested iHeps but in
particular in +/, /, and FH-1 iHeps (Figure 2B, middle
and right panels).
In the clinic, the inefficiency of statins in reducing LDL-C
in some FH patients is partly due to increased PCSK9
expression, as this promotes LDLR degradation (Maxwell
et al., 2005). To confirmwhether PCSK9 is also upregulated
by statins in iHeps in vitro, we performed western blotting
of FH-1 and WT iHeps untreated or treated with simva-
statin, observing that the treatment increases PCSK9performed on three independent experiments; p values are indicated on
indicate SEM. Vehicle: DMSO.
(C) Western blotting shows that PCSK9 is induced by simvastatin in i
(D) LDL uptake capacity of healthy and heterozygous FH iHeps was mea
units. Cells were treated with simvastatin and/or PCSK9 antibodies
performed on three independent cell lines for both healthy (+/+, WT
heterozygous FH iHeps (+/, FH-1, and FH-2 iHeps). p Values are indic
with Dunnett’s multiple comparison; error bars indicate SEM.expression (Figure 2C). We then developed a 48-well-based
assay to compare systematically the effect of different con-
centrations of statins and PCSK9 antibodies on LDL uptake
in iHeps. In isolation, PCSK9 antibodies were more potent
than simvastatin in inducing LDL uptake in healthy and
heterozygous FH iHeps, and their combination did not in-
crease it further (Figure 2D). Neither simvastatin nor PCSK9
antibodies had any effect on LDL uptake in/ iHeps (Fig-
ure S3F). These in vitro results reproduce clinical observa-
tions showing that PCSK9 antibodies are a remarkable
substitute for statins in treating heterozygous FH patients
but are ineffective for homozygous FH patients (Stein
et al., 2013).
Engrafted iHeps Reduce Plasma LDL-C Levels in an FH
Chimeric Mouse Model
To further expand our iHep platform and perform drug
testing in vivo, we crossed Ldlr/ mice (Ishibashi et al.,
1993) with Rag2//Il2rg/ mice, and so generated tri-
ple-knockout LRG mice (Figure 3A). LRG mice lack an
effective adaptive immune system, allowing the trans-
plantation of human iHeps into an LDLR null back-
ground without rejection. To demonstrate this, we
engrafted iHeps from FH iPSCs into LRG mice via intra-
splenic injection. To improve the repopulation efficiency,
we exposed mice to 3 Gy of g-ray radiation 24 hr prior to
engraftment to induce moderate liver injury and so
enable proliferation of the engrafted iHeps. In addition,
we suspended the injected iHeps in 50% Matrigel to pro-
vide a microenvironment that facilitates migration into
the liver from the spleen (Figure 3B). The evidence of
liver repopulation with iHeps in LRG mice was assessed
by immunohistochemical staining for LDLR, human
albumin (hALB), and human nuclear antigen (hNA) (Fig-
ures 3C and 3D). To determine iHep engraftment effi-
ciency, we first stained chimeric mouse liver sections
with hALB antibodies and then scanned the whole sec-
tions to quantify hALB+ areas (Figures 3E, 3F, and S4A).
With this strategy, we were able to assess iHep engraft-
ment efficiency in multiple lobules and lobes rather
than in small-area images. All tested iHeps showed signif-
icant repopulation in LRG mouse liver 3 weeks after
transplantation, based on hALB staining, although with
slight variations in efficiency (ranging from 5% tothe graphs and were obtained using a Kruskal-Wallis test; error bars
Heps.
sured with microplate readers and indicated as relative fluorescence
for 16 hr on days 17–21 of differentiation. Statistical tests were
iHeps, and iHeps from another unaffected FH family member) and
ated on the figure and were obtained using one-way ANOVA adjusted
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10%) (Figure 3G). Because hALB is a secreted protein
and dispersion could influence the assessment, we also
used hNA to calculate iHep engraftment efficiency,
which showed a moderately higher value than with
hALB (15% on average for different iHeps) (Figure 3H).
No evidence of hALB+ or hNA+ cells was observed in LRG
mouse liver engrafted with vehicle (Figures 3D and S4A).
Likewise, there was no positive signal in the spleen
of animals injected with iHeps (Figure S4B), demon-
strating that transplanted cells do not engraft there after
injection.
Fed a normal diet, LRG mice engrafted with +/+ iHeps
had lower, but not statistically significant, levels of plasma
LDL-C (n = 6, 57.9 ± 3.1 mg/dL) compared with vehicle
(n = 4, 112.7 ± 20.6 mg/dL) 3 weeks after transplantation,
while +/ iHeps (n = 4, 72.5 ± 12.0 mg/dL) and FH-1 iHeps
(n = 5, 70.1 ± 12.7 mg/dL) were less effective (Figure 3I, left
panel). As expected, / iHeps had no effect on LDL-C
clearance (n = 6, 119.6 ± 6.9mg/dL) compared with vehicle
(Figure 3I, left panel). We then fed LRG mice with a high-
fat, high-cholesterol (HFHC) diet to see whether this
magnifies differences in LDL-C lowering after iHep trans-
plantation. LRG mice showed around a 3-fold increase in
LDL-C plasma after 1 week on HFHC diet (Figure 3I, right
panel). Under this condition, transplanted +/+ iHeps
(n = 5, 275.1 ± 19.0mg/dL), and to a lesser extent +/ iHeps
(n = 6, 439.3 ± 35.6 mg/dL) and FH-1 iHeps (n = 6, 414.7 ±
42.0 mg/dL), significantly downregulated plasma LDL-C
levels compared with vehicle (n = 6, 606.7 ± 27.7 mg/dL)
or/ iHeps (n = 6, 617.3± 22.8mg/dL) (p < 0.01, Figure 3I,
right panel). To assess the long-term effects of engrafted
iHeps compared with primary human hepatocytes (pHH),Figure 3. Generation of Chimeric Mice Engrafted with FH iHeps
(A) Schematic view of derivation of LRG mice.
(B) Strategy for generation of FH chimeric mice, and assessment of L
(C and D) Immunohistochemical staining for LDLR, hNA, and hALB in
(vehicle). Zoomed images for LDLR and hNA are shown. Scale bars re
(E and F) Whole-slide scan image (E) and snapshot images (F) of hALB
snapshot images in the whole section is shown in the corner. Scale bar
three images in F).
(G) Scatter diagram shows the percentage of engrafted hALB+ iHeps in
Each dot represents one mouse with no less than four sections analy
(H) Bar graph shows the percentage of repopulated hNA+ iHeps in LRGm
iHeps 3 1, +/ iHeps 3 2, and / iHeps 3 1); quantification of
Experimental Procedures for detailed description). Error bars indicate
(I) Plasma LDL-C levels in LRGmice engrafted with the indicated iHeps
at the indicated time points after iHep transplantation; n indicates nu
using a Kruskal-Wallis test; error bars indicate SEM.
(J) Percentage change of plasma LDL-C from baseline at weeks 1, 4,
engrafted with +/+ iHeps or pHH; n indicates number of mice. p Values
test; error bars indicate SEM.
(K) Immunohistochemical staining for hALB and hNA in LRGmouse liv
Scale bars represent 200 mm.we tested LDL-C levels 12 weeks after transplantation
of +/+ iHeps and pHH into LRG mice fed with HFHC
diet, observing notable and rather comparable plasma
LDL-C clearance in both cases compared with vehicle
(p < 0.05, Figure 3J). The evidence of engrafted cells at
this time point was assessed by staining for hALB and
hNA in liver sections (Figure 3K). Overall, these experi-
ments demonstrate that transplantation of LDLR-compe-
tent but not LDLR null iHeps promotes plasma LDL-C
clearance in LRG mice.
Alirocumab Shows Stronger LDL-Lowering Ability
than Statins in Chimeric LRGMice
We then used HFHC diet to assess the effect of PCSK9 anti-
bodies compared with statins on iHeps engrafted into LRG
mice (Figure 4A). Importantly, we used a clinical-grade
formulation of PCSK9 monoclonal antibodies, alirocu-
mab (Sanofi and Regeneron Pharmaceuticals), which has
completed phase III clinical trials (Robinson et al., 2015)
and was approved by the Food and Drug Administration
in July 2015 as a cholesterol-lowering drug. Alirocumab
at 10 mg/kg/week enhanced plasma LDL-C clearance by
engrafted +/ iHeps (Figure 4B; n = 3, percentage reduction
from baseline 50.06% ± 7.38%, p < 0.05 compared
with +/ iHeps alone) and FH-1 iHeps (Figure 4C; n = 3, per-
centage reduction frombaseline 61.29% ± 10.80%, p < 0.05
compared with FH-1 iHeps alone) 21 days after treatment.
Simvastatin at 10 mg/kg/day also reduced LDL-C clearance
by engrafted +/ iHeps (n = 3, percentage reduction
33.37% ± 10.55%, p > 0.05 compared with iHeps alone)
and FH-1 iHeps (n = 5, percentage reduction 28.39% ±
9.55%, p > 0.05 compared with iHeps alone), but lessDL-C level and endothelial function.
LRG mouse liver repopulated with the indicated iHeps or Matrigel
present 50 mm (C) and 200 mm (D).
staining in mouse liver repopulated with +/+ iHeps. The location of
s represent 2 mm (E and top left image in F) and 400 mm (remaining
LRG mouse liver calculated based on whole-slide scanning images.
zed. Error bars indicate SEM.
ouse liver (n = 4, including sections of LRGmice engrafted with +/+
hNA+ cells was performed by manual counting (see Supplemental
SEM.
under normal diet (left panel) and HFHC diet (right panel) assessed
mber of mice. p Values are indicated on the figure and were obtained
8, and 12 post-transplantation in LRG mice fed with HFHC diet and
are indicated on the figure and were obtained using a Kruskal-Wallis
er repopulated with +/+ iHeps and pHH 12 weeks post-engraftment.
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Figure 4. In Vivo Drug Testing with FH Chimeric Mice
(A) Strategy for in vivo drug testing using LRG mice engrafted with FH iHeps.
(B–D) Percentage change of plasma LDL-C from baseline at the indicated time points after iHep transplantation in LRGmice fed with HFHC
diet and treated with simvastatin and/or PCSK9 antibodies; n indicates number of mice. p Values are indicated on the figure panel and were
obtained using a Kruskal-Wallis test and error bars indicate SEM.significantly than alirocumab, and their combination was
not synergistic (Figures 4B and 4C). Moreover, in chimeric
mice engrafted with / iHeps, alirocumab alone had
no effect, while simvastatin alone or combined with aliro-
cumab had only a modest effect on LDL-C clearance (Fig-
ure 4D). This moderate effect of simvastatin (alone or in
combination) on engrafted / iHeps is likely due to inhi-612 Stem Cell Reports j Vol. 8 j 605–618 j March 14, 2017bition of HMG-CoA reductase (Endo, 1992). Notably, the
observed percentage reduction of plasma LDL-C with aliro-
cumab in LRGmice engrafted with +/ iHeps or FH-1 iHeps
is similar to that reported in human studies (Robinson
et al., 2015; Roth et al., 2012). These results show the po-
tential utility of LRGmice engrafted with FH iHeps for pre-
clinical testing of novel drugs for FH.
Improvement of Endothelium-Dependent
Vasodilation in Chimeric LRGMice by Alirocumab
and Statins
One consequence of FH is the accelerated development
of atherosclerosis on the arterial wall (Vanhoutte et al.,
2016), but we did not observe any obvious development
of atherosclerotic lesions (assessed by oil red O staining)
in our LRG mice fed with HFHC diet (data not shown).
This is likely due to their compromised immune system
and the relatively short period on the HFHC diet. Impaired
endothelial function is an early indicator of atherosclerosis
in children and young adults with FH (Wiegman et al.,
2004), which manifests as reduced flow-mediated endo-
thelium-dependent vasodilation (EDV) and increased
proinflammatory gene expression, while EDV in response
to glyceryl trinitrate in these patients is comparable with
that in control subjects (Aggoun et al., 2000). We found
that EDV induced by cumulative concentrations of acetyl-
choline (ACh) was significantly improved in aortic rings
of LRGmice engrafted with +/+ iHeps compared with LRG
mice engrafted with FH-1 iHeps, +/ iHeps, or / iHeps
(p < 0.01, Figure 5A). However, endothelium-independent
vasodilation induced by sodium nitroprusside was similar
in endothelium-denuded aortic rings from all LRG groups
(Figure 5B). Alirocumab at 10 mg/kg/week improved EDV
significantly in LRG mice engrafted with +/ (p < 0.01) or
FH-1 iHeps (p < 0.05, Figures 5C and 5D), while there was
no effect on LRGmice engrafted with / iHeps or vehicle
(Figures 5E and 5F). In contrast, 10 mg/kg/day simvastatin
improved EDV in aortas of all groups (Figures 5C–5F), sup-
porting the knowledge that the vasoprotective effect of sim-
vastatin is partially independent of LDLR status (Tian et al.,
2011). Moderate synergistic effect of simvastatin and aliro-
cumab on EDV in aortic rings was observed in LRGmice en-
grafted with +/ iHeps or FH-1 iHeps, but not/ iHeps or
vehicle (Figures 5C–5F). Simvastatin or alirocumab did not
have any effect on sodium nitroprusside-induced relaxa-
tion in aortic rings from LRGmice engraftedwith all groups
of iHeps or vehicle (Figures S5A–S5D). Furthermore, RT-
qPCR of aorta samples from LRG mice engrafted with +/
iHeps showed that treatmentwith alirocumab, simvastatin,
or their combination significantly reduced the expression
of cytokines, chemokine receptors, and adhesionmolecules
related to vascular inflammation (Figure S5E). Therefore,
EDV in aortas is a good readout for monitoring the conse-
quences of FH in LRG mice engrafted with FH iHeps, and
is responsive to treatmentwith PCSK9 antibodies or statins.DISCUSSION
Patient-specific iPSCs can be differentiated into disease-
relevant cells, thus providing an unlimited source of hu-man cells for in vitro studies (Grskovic et al., 2011). Using
this disease-in-a-dish approach, multiple human condi-
tions including liver diseases have been modeled (Li
et al., 2012; Rashid et al., 2010; Zhang et al., 2011). In
this study, we have employed patient-specific FH iPSCs
and genetically engineered isogenic FH iPSCs to create a
platform for in vitro and in vivo drug testing of LDL-C-
lowering therapies.
Several groups have previously reported FH iPSCs
harboring mutations in LDLR and PCSK9 and the ability
of the derived iHeps to increase LDL uptake in vitro upon
treatment with statins (Cayo et al., 2012; Ramakrishnan
et al., 2015; Si-Tayeb et al., 2016). Our work has focused
on testing therapies for FH, in particular anti-PCSK9 anti-
bodies, in vitro and in vivo using FH iHeps, although this
has been previously studied in vitro using pHH (Zhang
et al., 2012). Likewise, FH disease modeling with isogenic
iPSCs, which allow healthy versus diseased comparison of
iHeps that share the same genetic background, had not
been described beforehand. The addition of isogenic iPSCs
may overcome the shortcomings of using a small number
of patient-specific iPSCs and clones for identifying FH phe-
notypes in this study. Consistent with previous studies us-
ing FH iHeps (Cayo et al., 2012; Ramakrishnan et al., 2015;
Si-Tayeb et al., 2016), our in vitro experiments confirm that
statins increase LDL uptake in FH iHeps and also demon-
strate a concomitant reduction in TC and APOB level. To
facilitate the systematic screening of LDL-C-lowering med-
ications with FH iHeps, we designed a 48-well assay based
on labeled LDL capture. This assay showed higher efficacy
in increasing LDL capture of PCSK9 antibodies compared
with statins, and in the future may prove useful for identi-
fying new candidate drugs for treating FH through system-
atic screening. In this regard, our assaymay be adaptable to
96-well plates through further optimization.
Human liver chimeric mice carrying human pHH can
facilitate in vivo study of viral hepatitis infections (Bissig
et al., 2010; Carpentier et al., 2014) and liver genetic dis-
eases (Bissig-Choisat et al., 2015; Yusa et al., 2011), and
the testing of small molecular drug candidates and biolog-
ical components including antibodies (Legrand et al.,
2009). Embryonic stem cell (ESC)- or iPSC-derived iHeps
have been used to generate chimeric mice by engrafting
them into the liver of non-obese diabetic severe combined
immunodeficient (NOD-SCID) mice (Chen et al., 2012),
NOD/Lt-SCID/IL-2Rg/ (NSG) mice (Liu et al., 2011), or
uPA transgenic mice (Basma et al., 2009; Carpentier et al.,
2014), where iHeps showed further maturation and regen-
eration potential and displayed key activities of primary he-
patocytes. Our study has produced a mouse model that
lacks the gene (Ldlr) involved in a human disease (FH)
and is engrafted with patient-specific iHeps to mimic the
specific human disease condition and perform in vivoStem Cell Reports j Vol. 8 j 605–618 j March 14, 2017 613
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Figure 5. Alirocumab and Statins Improve EDV in Chimeric LRG Mice
(A and B) EDV in response to cumulative concentrations of acetylcholine (ACh) (A) and endothelium-independent vasodilation to sodium
nitroprusside (SNP) (B) in aortas (precontracted with phentolamine [Phe]) from LRGmice fed with HFHC diet. Mice were engrafted with the
indicated iHeps or vehicle; n indicates number of mice. p Values are indicated on the figure and were obtained using two-way ANOVA
adjusted with Dunnett’s multiple comparison; error bars indicate SEM.
(C–F) EDV in response to ACh in aortae (precontracted with Phe) from LRGmice fed with HFHC diet. Mice were engrafted with the indicated
iHeps and treated with simvastatin (daily) and/or alirocumab (weekly); n indicates number of mice. p Values are indicated on the figure
and were obtained using two-way ANOVA adjusted with Dunnett’s multiple comparison; error bars indicate SEM.drug testing. This approach has significant advantages over
studies using Ldlr knockout mice alone (Ishibashi et al.,
1993), as endogenous hepatocytes in the latter mouse
model are not responsive to drugs modulating the LDLR
pathway. A recent study showed engraftment of FH pa-
tient-specific iHeps injected subcutaneously rather than
into the liver parenchyma of Rag1//Ldlr/ mice, but
the authors did not perform an assay to demonstrate func-614 Stem Cell Reports j Vol. 8 j 605–618 j March 14, 2017tional recovery (Ramakrishnan et al., 2015). Another report
demonstrated the feasibility of directly engrafting FH (due
to compound heterozygosity in LDLR gene) pHH into
Fah//Rag2//Il2rg/ mice, and the phenotype of FH
was successfully rescued by LDLR gene therapy using ad-
eno-associated virus (Bissig-Choisat et al., 2015). Because
of the lack of Fah, these mice had higher repopulation effi-
ciency (>70%) (Bissig-Choisat et al., 2015) than our mice.
However, a problem of this approach is that a population
of mouse hepatocytes with intact LDLR remains while
the engrafted patients’ pHH did not contain functional
LDLR, which can be confounding factors when performing
in vivo testing of drugs acting on the LDLR pathway.
Moreover, primary FH hepatocytes are difficult to obtain
and cannot be expanded in vitro. Although liver repopula-
tion in our chimeric mice is significantly lower than for
Fah//Rag2//Il2rg/ mice engrafted with pHH (Azuma
et al., 2007; Bissig-Choisat et al., 2015), it is comparable
with results of recent reports describing NSG mice or
Gunn rats (amodel of Crigler-Najjar syndrome 1) engrafted
with iPSC-derived iHeps (2%–17% [Liu et al., 2011] and
5.1% [Chen et al., 2015]). In the future, crossing our LRG
mice with Fah knockout mice could help achieve higher
liver chimerism, and thus further upgrade in vivo drug
testing studies using engrafted FH iHeps. It should also
be considered that mice and humans bear differences
in lipoprotein metabolism, and therefore it may be desir-
able to genetically engineer other mammalian species
(e.g., rabbits) (Shiomi and Ito, 2009) for more accurate
studies using transplanted human FH iHeps. Nevertheless,
despite the physiological differences between mice and
humans and the moderate chimerism of our own model,
the lowering of plasma LDL-C achieved with LDLR-
competent iHeps was significant, while FH iHeps were
less effective but exhibited good response to statins and
particularly to PCSK9 antibodies. Besides plasma LDL-C
levels, we measured endothelial function in aortas of
LRG mice to assess the efficacy of engrafted iHeps and
these two medications in vivo, as this parameter is
affected early in patients with FH (Wiegman et al.,
2004). Our results showed that cell therapy and the two
medications could improve EDV in chimeric mice, indi-
cating that endothelial function can be used as a param-
eter to evaluate disease progression during preclinical
testing in chimeric LRG mice or other similar animal
models. Importantly, we also noticed that the engrafted
iHeps could be maintained in LRG mouse liver, and
were functional, for at least 3 months. Overall, these re-
sults highlight the potential relevance of transplanting
iPSC-derived iHeps for the treatment of hereditary meta-
bolic liver disorders (Cantz et al., 2015), and the use of
chimeric animals humanized with disease-specific iHeps
for preclinical evaluation of novel therapies. However,
the long-term therapeutic efficacy of iPSC-based ap-
proaches remains unclear, and future studies are necessary
to address this as well as safety concerns.
In summary, our work provides a state-of-the-art in vitro
and in vivo platform for testing drugs and experimental cell
therapies using FH iHeps. Similar platforms using other
gene knockout mice and alternative patient-specific iHeps
may be useful to investigate pathological mechanismsand performpreclinical studies for unrelated inherited liver
diseases.EXPERIMENTAL PROCEDURES
DNA Sample Preparation and Sequencing
Genomic DNAwas extracted from blood of subjects with FH using
the QIAamp DNA blood kit (Qiagen). All exons of the LDLR gene
locus were sequenced by Sanger sequencing, and mutations were
identified by aligning with the reference sequence GenBank:
NM_000527.4 from NCBI.
Cell Culture and Reprogramming
Urinary cells were obtained and expanded according to our pub-
lished protocol (Zhou et al., 2012) with approval from the Institu-
tional Review Board (HKCTR-725, http://www.hkclinicaltrials.
com). Written informed consent from all patients is available
upon request. Cells were reprogrammed with episomal vectors
(Addgene) that encode human OCT4, SOX2, KLF4, MYC, LIN28,
and SV40LT (Yu et al., 2009), using a previously reported protocol
(Yu et al., 2011) with the combination of small molecular
compounds containing 0.5 mM PD0325901 (Stemgent), 3 mM
CHIR99021 (Stemgent), 0.5 mM A-83-01 (Stemgent), 1,000 U/mL
human LIF (Millipore), 10 mM Y27632 (Sigma-Aldrich), and
100 ng/mL basic fibroblast growth factor (Peprotech). Human
ESC-like colonies were picked at around day 25 and expanded in
mTeSR1 (StemCell) onMatrigel (Corning)-coated plateswith Accu-
tase (Sigma-Aldrich).
Knockout Cell Line Generation
Sigma-Aldrich donated the LDLR ZFNs. LDLR-ZFN mRNAs were
generated through in vitro transcription of LDLR-ZFN plasmids
with a MessageMAX T7 ARCA-Capped Message Transcription Kit
(Cambio) according to the manufacturer’s specifications. The
parental iPSC clone was reported previously (UC C0406-iPS C4)
(Zhou et al., 2011). Detailed procedures are described in Supple-
mental Experimental Procedures.
In Vitro Differentiation of iPSCs into iHeps
Human iPSCs were differentiated into iHeps as reported previously
(Kajiwara et al., 2012) but with small modifications at the endo-
derm induction stage: RPMI-1640 containing 100 ng/mL activin
A (PeproTech) and 25 ng/mLWNT3a (R&D Systems)was employed
for 1 day when the iPSCs had reached around 70% confluence,
after which WNT3a was omitted from the medium for the
following 2 days. HGF was purchased from PeproTech, Oncostatin
M from R&D Systems, RPMI-1640, KnockOut DMEM, KnockOut
Serum Replacement, and GlutaMAX Supplement from Life Tech-
nologies, DMSO from Sigma-Aldrich, and the HCM Bullet Kit
from Lonza.
hALB, TC, and APOB Measurements
hALB, TC, and APOB measurements were performed on superna-
tants of day-17 to -18 (24-hr interval) iHeps culture by ELISA using
a kit (Cell Biolabs for hALB and TC; MABTECH for APOB), in 96-
well assay plates according to the manufacturer’s specifications.Stem Cell Reports j Vol. 8 j 605–618 j March 14, 2017 615
LDL Uptake Assays
LDL uptake assays employed fluorescently labeled LDL and
3,30-dioctadecylindocarbocyanine (DiI)-LDL (Life Technologies),
which were measured by microscopy or flow cytometry.
Detailed procedures are described in Supplemental Experimental
Procedures.
PCSK9 Antibodies and Simvastatin Treatments
In Vitro
iPSCswere split onto 48-well plates and differentiated into iHeps as
described above. At days 17–21 of differentiation, iHeps were
treated with simvastatin and/or PCSK9 monoclonal antibodies
(Cayman Chemical) for 16 hr and then incubated with 5 mg/mL
DiI-LDL for 1 hr. Cells were washed with Ca2+/Mg2+-free PBS
(CMF-PBS, Hyclone) and the DiI-LDL signal was captured with a
CLARIOstar microplate reader (BMG LABTECH). Cells were then
fixed with 4% paraformaldehyde and stained with ASGPR anti-
bodies (Santa Cruz Biotechnology). Signal was read again with
the microplate reader. Fluorescence signals were analyzed by
MARS Data Analysis Software and normalized by the number of
iHeps indicated by the ASGPR signal. Relative fluorescence units
refer to the fold change of fluorescence values compared with
the baseline (null treatment).
Chimeric Mice Generation
The animal study was approved by the Institutional Review
Board (CULATR-2592-11 and 3003-13). Ldlr–/– mice (B6.129S7-
Ldlrtm1Her/J, The Jackson Laboratory) were crossed with Rag2//
Il2rg–/– mice (available in our lab by crossing of B6(Cg)-
Rag2tm1.1Cgn/J mice with B6.129S4-Il2rgtm1.wWjl/J mice purchased
from The Jackson Laboratory) to generate LRG mice. Genotype
was confirmed by PCR and sequencing using genomic DNA
from mouse ear. As recipient for iHeps, we used 8- to 16-week-
old LRG mice. Mice were irradiated with 3 Gy of g-ray using a
Gammacell 3000 Elan II (MDS Nordion) machine 24 hr prior to
cell engraftment. A total of 106 iHeps or pHH (Lonza) suspended
in 50 mL of 5.1 mg/mL Matrigel (Basement Membrane Matrix,
Corning 354234) in CMF-PBS solution were engrafted into mouse
liver by intrasplenic injection.
In Vivo Drug Testing
For the HFHC diet group, mice were fed with HFHC diet from
7 days prior to engraftment. For the drug treatment group, drugs
were administered from 7 days post-engraftment. The clinical-
grade PCSK9 monoclonal antibody formulation alirocumab
(SAR236553/REGN727, Sanofi and Regeneron Pharmaceuticals)
was injected subcutaneously (10 mg/kg/week) with or without
simvastatin (Zocor; Merck Sharp & Dohme) treatment
(10 mg/kg/day in drinking water) for 21 days. Blood samples
were collected from the facial vein at the indicated time points
and the day of engraftment of iHeps was set as day 0 or baseline.
Plasma LDL-C level was evaluated using an L type LDL-C detection
kit (Wako). Functional studies of EDV in response to AChwere per-
formed in aortas precontracted with phentolamine using a myo-
graph (Danish Myo Technology) as previously reported (Tian
et al., 2011). Detailed procedures are described in Supplemental
Experimental Procedures.616 Stem Cell Reports j Vol. 8 j 605–618 j March 14, 2017Statistical Analyses
Results are represented as the mean ± SEM unless otherwise indi-
cated. Statistical analysis was performed with one-way or two-
way ANOVA implemented in Prism 6 (version 6.03), or with
Kruskal-Wallis test implemented in Scipy (version 0.18.1). All sta-
tistical tests were evaluated at a significance level of p < 0.05.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, five figures, and two tables and can be found
with this article online at http://dx.doi.org/10.1016/j.stemcr.
2017.01.027.
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